We gathered this footage back in September at the Think Equity G5 Growth Conference. In this segment, Gulfo, CEO of Electro-Optical Sciences, Inc. (MELA) discusses MelaFind - a handheld device that capture images of suspicious pigmented skin lesions. The data is then analyzed against a database of melanomas and benign lesions. The “Lesion Classifier” recommends whether the lesion should be biopsied.
With assistance provided by MelaFind, physicians could diagnose more melanomas at the earliest curable stage, reducing both treatment costs and the number of unnecessary biopsies. Gulfo describes MelaFind as “better, cheaper medicine.”
Electro-Optical Sciences initiated a clinical trial back in January and anticipates submitting the PMA to the FDA by the end of 2007; in October 2006, EOS received notification of an Expedited Review designation.
Skin cancer is the most common form of cancer in the U.S., with over one million cases diagnosed each year. It also is one of the fastest growing cancers in the U.S. and the leading cause of cancer death in women ages 25-30. Melanoma accounts for only 4% of skin cancer cases, but is responsible for 75% of skin cancer deaths.
Click below to view video